Elicio Therapeutics, Inc.

Stage 4 · Declining · week 16

As of Oct 22, 2026, Elicio Therapeutics is in Stage 4, the downtrend phase, now in week 16 (since Jul 1, 2026). It closed at $1.94, 86.9% below its 52-week high and below its 200-day average, which is falling.

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. More about the company

$1.94

+13.38% today

$52.6M · Micro cap

Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is ELTX early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…

Stage Cycle Timeline2023-08-16 → 2026-10-22

S4 23w

S1 17w

S2 19w

S4 16w

2023-08-162026-10-22

S1S2S3S4Setup score (0–10, dashed line at 5)

S2 1w → S3 9w → S4 23w → S1 4w → S2 8w → S3 5w → S4 9w → S1 17w → S2 10w → S3 7w → S4 2w → S3 1w → S2 19w → S3 10w → S4 6w → S1 2w → S2 9w → S3 3w → S2 1w → S3 2w → S4 16w current

Total tracked: 164 weeks across 21 stage runs.

ELTX among Biotechnology466th of 591 by relative strength

All 591 →

Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#	Stock	Stage	RS	1M
1	GTBPGT Biopharma, Inc.	Stage 2 · wk 7	99	−22.3%
2	IOVAIovance Biotherapeutics, Inc.	Stage 2 · wk 18	99	+38.8%
3	SLSSELLAS Life Sciences Group, Inc.	Stage 3 · wk 4	99	−1.5%
4	MRNAModerna, Inc.	Stage 2 · wk 17	99	+11.3%
5	TWSTTwist Bioscience Corporation	Stage 2 · wk 39	99	−14.5%
6	KODKodiak Sciences Inc	Stage 2 · wk 4	99	+172.1%
7	ERASErasca, Inc.	Stage 3 · wk 5	99	+0.7%
8	CLYMClimb Bio, Inc.	Stage 3 · wk 3	99	−15.8%
…466	ELTXElicio Therapeutics, Inc.	Stage 4 · wk 16	11	+3.7%

vs 52W High

-86.9%

$1.55 lo$14.85 hi

86.9% below 52W high, deep Stage 4 damage

In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.

Stage Maturity

Week 16

1w13w26w

Week 16, established downtrend

How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.

vs 200 DMA

-72.2%

200 DMA: $6.97 · sloping down

In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.

Rel Volume

1.67x

vs 50-day avg

High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.

Trend Health

↓

Short-term trend rolling over

Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.

+3.7%

-35.3%

-83.6%

YTD

-75.9%

-79.5%

Scan Membership

Breakout Watch

Latest: 2025-06-18

4 appearances in last 60 days. First seen: 2023-06-12.

A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.

Recent Stage Timeline

2026-10-22S4

Wk 16 · Vol 1.67x

2026-10-21S4

Wk 16 · Vol 0.83x

2026-10-20S4

Wk 16 · Vol 0.90x

2026-10-19S4

Wk 16 · Vol 0.98x

2026-10-16S4

Wk 16 · Vol 1.11x

2026-10-15S4

Wk 15 · Vol 0.56x

2026-10-14S4

Wk 15 · Vol 1.20x

2026-10-13S4

Wk 15 · Vol 0.74x

2026-10-12S4

Wk 15 · Vol 0.52x

2026-10-09S4

Wk 15 · Vol 0.97x

2026-10-08S4

Wk 14 · Vol 0.85x

2026-10-07S4

Wk 14 · Vol 0.44x

Moving averages & range

50 DMA

$2.22

200 DMA

$6.97

52W High

$14.85

52W Low

$1.55

5D Low

$1.55

Resistance levels (recent highs)

20d High

$1.94

60d High

$3.19

120d High

$14.85

250d High

$14.85

Next resistance

+64.4%

to 60d High

ROE

-774.6%

Profit margin 0.0%

Dividend Yield

0.00%

P/B 5.4

Elicio Therapeutics: quick answers

What stage is Elicio Therapeutics in?

As of Oct 22, 2026, Elicio Therapeutics (ELTX) is in Stage 4, the downtrend phase. It entered Stage 4 on Jul 1, 2026 and is in week 16. What the four stages mean

Is Elicio Therapeutics in an uptrend?

No. Elicio Therapeutics is in a Stage 4 downtrend. It trades 72.2% below its 200-day average, which is falling.

How far is Elicio Therapeutics from its 52-week high?

Elicio Therapeutics closed at $1.94 on Oct 22, 2026, 86.9% below its 52-week high of $14.85. Its 52-week low is $1.55.

How has Elicio Therapeutics performed over the past year?

As of Oct 22, 2026, Elicio Therapeutics is down 79.5% over the past year and down 75.9% so far in 2026.

Which sector and industry is Elicio Therapeutics in?

Elicio Therapeutics is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company also develops ELI-007, a multivalent lymph node-targeted AMP peptide treatment for mutant b-raf murine sarcoma viral oncogene homolog B1-(BRAF) driven cancers, and ELI-008, a multivalent lymph node-targeted AMP peptide vaccine in preclinical studies for the treatment of mutated tumor protein p53-expressing cancers. Elicio Therapeutics, Inc. is headquartered in Boston, Massachusetts.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.